Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC08/r + PEG-IFN + ribavirin in treatment-naïve genotype 1 chronic hepatitis C (non-cirrhotic)
CTR20150846Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of danoprevir in chronic hepatitis C virus infection, sponsored by Ascletis Pharma Inc.. Started Feb 2016; status: completed.
02
Drugs
danoprevir
03
Conditions
chronic hepatitis C virus infection
Beyond the preview
Go deeper on CTR20150846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150846.